PARP1 and prostate carcinoma: Rucaparib, another PARP inhibitor (rucaparib is not covered by health insurance for prostate cancer in Japan but is approved by the FDA in the U.S.), was evaluated in the TRIRON2 trial, a phase two study targeting mCRPC cases with mutations in DNA repair pathway-related genes [34].